Not an actual patient
Not an actual patient
Not an actual patient
Not an actual patient
Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
Not an actual patient
Not an actual patient
Not an actual patient
Not an actual patient
Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
References
1. Zenke FT, et al. Mol Cancer Ther. 2020;19(5):1091-1101; 2. Zimmermann A, et al. Mol Cancer Ther. 2022;21(6):859-870.
The mechanisms in the DDRiver™ clinical trials program are under clinical investigation and have not been proven to be safe and effective. There is no guarantee that any therapies in the clinical trials program will be approved in the sought-after indication by any health authority worldwide. Clinical trial information is available at www.clinicaltrials.gov.
This website is intended for healthcare professionals in the US and Canada. For patient information, click here: https://clinicaltrials.emdgroup.com/.
© 2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. DDRiver™ is a trademark of Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada.
Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.
US-MULO-00083 June 2024